Accurate quantification of chromosomal lesions via short tandem repeat analysis using minimal amounts of DNA

Background Cytogenetic aberrations such as deletion of chromosome 5q (del(5q)) represent key elements in routine clinical diagnostics of haematological malignancies. Currently established methods such as metaphase cytogenetics, FISH or array-based approaches have limitations due to their dependency on viable cells, high costs or semi-quantitative nature. Importantly, they cannot be used on low abundance DNA. We therefore aimed to establish a robust and quantitative technique that overcomes these shortcomings. Methods For precise determination of del(5q) cell fractions, we developed an inexpensive multiplex-PCR assay requiring only nanograms of DNA that simultaneously measures allelic imbalances of 12 independent short tandem repeat markers. Results Application of this method to n=1142 samples from n=260 individuals revealed strong intermarker concordance (R²=0.77–0.97) and reproducibility (mean SD: 1.7%). Notably, the assay showed accurate quantification via standard curve assessment (R²>0.99) and high concordance with paired FISH measurements (R²=0.92) even with subnanogram amounts of DNA. Moreover, cytogenetic response was reliably confirmed in del(5q) patients with myelodysplastic syndromes treated with lenalidomide. While the assay demonstrated good diagnostic accuracy in receiver operating characteristic analysis (area under the curve: 0.97), we further observed robust correlation between bone marrow and peripheral blood samples (R²=0.79), suggesting its potential suitability for less-invasive clonal monitoring. Conclusions In conclusion, we present an adaptable tool for quantification of chromosomal aberrations, particularly in problematic samples, which should be easily applicable to further tumour entities.

[1]  O. Fuchs Recent Developments in Myelodysplastic Syndromes , 2019 .

[2]  A. Trumpp,et al.  Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure. , 2016, Blood.

[3]  R. Schlenk,et al.  Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5) , 2016, Leukemia.

[4]  Martin C. Müller,et al.  Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML , 2015, Annals of Hematology.

[5]  Peter Gill,et al.  Genotyping and interpretation of STR-DNA: Low-template, mixtures and database matches-Twenty years of research and development. , 2015, Forensic science international. Genetics.

[6]  G. Mufti,et al.  High concordance of genomic and cytogenetic aberrations between peripheral blood and bone marrow in myelodysplastic syndrome (MDS) , 2015, Leukemia.

[7]  R. Bejar,et al.  Recent developments in myelodysplastic syndromes. , 2014, Blood.

[8]  A. Trumpp,et al.  Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit. , 2014, Cell stem cell.

[9]  F. Solé,et al.  Will a peripheral blood (PB) sample yield the same diagnostic and prognostic cytogenetic data as the concomitant bone marrow (BM) in myelodysplasia? , 2012, Leukemia research.

[10]  J M Bienvenue,et al.  Sample-to-Result STR Genotyping Systems: Potential and Status. , 2012, Forensic science review.

[11]  C. Berthou,et al.  Molecular characterization of deletions of the long arm of chromosome 5 (del(5q)) in 94 MDS/AML patients , 2012, Leukemia.

[12]  R. Tubbs,et al.  Diagnostic yield of bone marrow and peripheral blood FISH panel testing in clinically suspected myelodysplastic syndromes and/or acute myeloid leukemia: a prospective analysis of 433 cases. , 2011, American journal of clinical pathology.

[13]  Xavier Robin,et al.  pROC: an open-source package for R and S+ to analyze and compare ROC curves , 2011, BMC Bioinformatics.

[14]  L. Trümper,et al.  FISH analysis of circulating CD34+ cells as a new tool for genetic monitoring in MDS: verification of the method and application to 27 MDS patients. , 2010, Leukemia research.

[15]  E. Thiel,et al.  Genome-wide DNA-mapping of CD34+ cells from patients with myelodysplastic syndrome using 500K SNP arrays identifies significant regions of deletion and uniparental disomy. , 2009, Experimental hematology.

[16]  J. Maciejewski,et al.  Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing. , 2008, Cancer genetics and cytogenetics.

[17]  A. Tchirkov,et al.  Gene dosage methods as diagnostic tools for the identification of chromosome abnormalities. , 2008, Pathologie-biologie.

[18]  C. O'keefe,et al.  Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. , 2008, Blood.

[19]  Thomas H Müller,et al.  New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. , 2007, Blood.

[20]  K. Halling,et al.  Fluorescence in situ hybridization in diagnostic cytology. , 2007, Human pathology.

[21]  B. Johansson,et al.  Proposals for standardized protocols for cytogenetic analyses of acute leukemias, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myeloproliferative disorders, and myelodysplastic syndromes , 2007, Genes, chromosomes & cancer.

[22]  M. McDevitt,et al.  Fluorescent in situ hybridization (FISH) in bone marrow and peripheral blood of leukemia patients: implications for occupational surveillance. , 2007, Mutation research.

[23]  I. Yaniv,et al.  Assessing quantitative chimerism longitudinally: technical considerations, clinical applications and routine feasibility , 2007, Bone Marrow Transplantation.

[24]  C. O'keefe,et al.  High-resolution genomic arrays facilitate detection of novel cryptic chromosomal lesions in myelodysplastic syndromes. , 2007, Experimental hematology.

[25]  R. Weksberg,et al.  A method for accurate detection of genomic microdeletions using real-time quantitative PCR , 2005, BMC Genomics.

[26]  A. Kasprzyk,et al.  Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome. , 2002, Blood.

[27]  B. Cheson,et al.  Report of an international working group to standardize response criteria for myelodysplastic syndromes. , 2000, Blood.

[28]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[29]  Jo-Anne Bright,et al.  Characterising stutter in forensic STR multiplexes. , 2012, Forensic science international. Genetics.

[30]  A. Cuneo,et al.  Multilineage involvement in the 5q- syndrome: a fluorescent in situ hybridization study on bone marrow smears. , 2001, Haematologica.

[31]  Iscn International System for Human Cytogenetic Nomenclature , 1978 .

[32]  W. Youden,et al.  Index for rating diagnostic tests , 1950, Cancer.